Pathological features of fatty liver disease
- PMID: 25109884
- DOI: 10.1053/j.gastro.2014.07.056
Pathological features of fatty liver disease
Abstract
Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are significant causes of chronic liver disease worldwide. Both are characterized by histological lesions that can include steatosis, and each can lead to cirrhosis. It might be possible for pathologists to identify lesions and patterns of ALD and NAFLD; we review these lesions and propose methods to distinguish between the disorders. Any form of ALD can lead to end-stage liver disease, according to long-term studies of biopsy specimens and patient outcomes. Although steatosis can be a significant cofactor in progression of established chronic liver disease, or even development of hepatocellular carcinoma, only steatohepatitis indicates the presence of progressive liver disease in patients with NAFLD. Pediatric and adolescent NAFLD differ from adult nonalcoholic steatohepatitis and should be recognized as distinct conditions. Benign and malignant liver tumors have been more frequently reported with the increasing prevalence of obesity and diabetes. Histological scoring systems for ALD and NAFLD have been proposed to monitor efficacy in clinical trials and serve as prognostic factors. We review what we have learned from pathological analyses about the development of these disorders and how this information might be used to detect and treat them.
Keywords: Diagnosis; Histology; NASH; Prognosis.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539. World J Gastroenterol. 2014. PMID: 25400438 Free PMC article. Review.
-
Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis?World J Gastroenterol. 2014 Nov 28;20(44):16474-9. doi: 10.3748/wjg.v20.i44.16474. World J Gastroenterol. 2014. PMID: 25469015 Free PMC article. Review.
-
Alcoholic liver disease/nonalcoholic fatty liver disease index: distinguishing alcoholic from nonalcoholic fatty liver disease.Eur J Gastroenterol Hepatol. 2013 Aug;25(8):899-904. doi: 10.1097/MEG.0b013e32835f0786. Eur J Gastroenterol Hepatol. 2013. PMID: 23426271
-
Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.Eur J Gastroenterol Hepatol. 2010 Jun;22(6):643-50. doi: 10.1097/MEG.0b013e32832ca0cb. Eur J Gastroenterol Hepatol. 2010. PMID: 19478676 Review.
-
Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management.Gastroenterology. 2016 Jun;150(8):1849-62. doi: 10.1053/j.gastro.2016.02.077. Epub 2016 Mar 10. Gastroenterology. 2016. PMID: 26971826
Cited by
-
A novel A2a adenosine receptor inhibitor effectively mitigates hepatic fibrosis in a metabolic dysfunction-associated steatohepatitis mouse model.Int J Biol Sci. 2024 Mar 3;20(5):1855-1870. doi: 10.7150/ijbs.92371. eCollection 2024. Int J Biol Sci. 2024. PMID: 38481815 Free PMC article.
-
Mic19 depletion impairs endoplasmic reticulum-mitochondrial contacts and mitochondrial lipid metabolism and triggers liver disease.Nat Commun. 2024 Jan 2;15(1):168. doi: 10.1038/s41467-023-44057-6. Nat Commun. 2024. PMID: 38168065 Free PMC article.
-
Fibrotic NASH in Individuals with Obesity: a Cross-sectional Analysis of the Prevalence of this Significant Milestone of Disease Progression and Accuracy of a Non-invasive Marker for its Screening.Obes Surg. 2024 Feb;34(2):389-395. doi: 10.1007/s11695-023-06998-1. Epub 2023 Dec 19. Obes Surg. 2024. PMID: 38110785
-
Hepatic Steatosis After Partial Pancreatectomy in a Cohort of Patients with Intraductal Papillary Mucinous Neoplasm.J Clin Exp Hepatol. 2023 Nov-Dec;13(6):955-961. doi: 10.1016/j.jceh.2023.05.006. Epub 2023 May 25. J Clin Exp Hepatol. 2023. PMID: 37975040
-
Agarwood extract mitigates alcoholic fatty liver in C57 mice via anti‑oxidation and anti‑inflammation.Mol Med Rep. 2023 Nov;28(5):210. doi: 10.3892/mmr.2023.13097. Epub 2023 Sep 29. Mol Med Rep. 2023. PMID: 37772395 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
